OBJECTIVE: The aim of the investigation was to study the effects of withdrawing selective serotonin reuptake inhibitor (SSRI) drugs in nursing home patients, who had no documented diagnosis or symptoms of depression. SETTING: The setting of the study was in 11 nursing homes in the county of Stockholm, Sweden. PARTICIPANTS: Participants were patients without dementia or history of depression who had received treatment with SSRI drugs for more than 6 months and who had no indications of anxiety disorder or major depression DESIGN: The included patients ( n=70) were randomized to either the intervention group (withdrawal of SSRI) or the control group (no change in treatment), 35 patients to each group. MAIN OUTCOME MEASURES: The patients were subjected to assessment using the following instruments: Montgomery-Asberg depression rating scale, global assessment for functioning, health index and a symptom assessment form. Assessment was made at the start of the study and at the 3-month and 6-month follow-ups. RESULTS: We found no significant difference between the intervention and control groups in any outcome measure. CONCLUSION: Treatment with SSRI drugs in patients without clinical major depression or anxiety disorder is often unjustified and should be discontinued.
RCT Entities:
OBJECTIVE: The aim of the investigation was to study the effects of withdrawing selective serotonin reuptake inhibitor (SSRI) drugs in nursing home patients, who had no documented diagnosis or symptoms of depression. SETTING: The setting of the study was in 11 nursing homes in the county of Stockholm, Sweden. PARTICIPANTS: Participants were patients without dementia or history of depression who had received treatment with SSRI drugs for more than 6 months and who had no indications of anxiety disorder or major depression DESIGN: The included patients ( n=70) were randomized to either the intervention group (withdrawal of SSRI) or the control group (no change in treatment), 35 patients to each group. MAIN OUTCOME MEASURES: The patients were subjected to assessment using the following instruments: Montgomery-Asberg depression rating scale, global assessment for functioning, health index and a symptom assessment form. Assessment was made at the start of the study and at the 3-month and 6-month follow-ups. RESULTS: We found no significant difference between the intervention and control groups in any outcome measure. CONCLUSION: Treatment with SSRI drugs in patients without clinical major depression or anxiety disorder is often unjustified and should be discontinued.
Authors: Johanna Ulfvarson; Johanna Adami; Bengt Ullman; Regina Wredling; Marie Reilly; Christer von Bahr Journal: Pharmacoepidemiol Drug Saf Date: 2003 Oct-Nov Impact factor: 2.890
Authors: A L Nyth; C G Gottfries; K Lyby; L Smedegaard-Andersen; J Gylding-Sabroe; M Kristensen; H E Refsum; E Ofsti; S Eriksson; S Syversen Journal: Acta Psychiatr Scand Date: 1992-08 Impact factor: 6.392
Authors: Kjell Lindström; Anders Ekedahl; Anders Carlsten; Jan Mårtensson; Sigvard Mölstad Journal: Scand J Prim Health Care Date: 2007-03 Impact factor: 2.581
Authors: Jennifer A Pruskowski; Sydney Springer; Carolyn T Thorpe; Michele Klein-Fedyshin; Steven M Handler Journal: Drugs Aging Date: 2019-12 Impact factor: 3.923
Authors: Amy T Page; Rhonda M Clifford; Kathleen Potter; Darren Schwartz; Christopher D Etherton-Beer Journal: Br J Clin Pharmacol Date: 2016-06-13 Impact factor: 4.335
Authors: Ellen Van Leeuwen; Mieke L van Driel; Mark A Horowitz; Tony Kendrick; Maria Donald; An Im De Sutter; Lindsay Robertson; Thierry Christiaens Journal: Cochrane Database Syst Rev Date: 2021-04-15
Authors: Adam L Gordon; Phillipa A Logan; Rob G Jones; Calum Forrester-Paton; Jonathan P Mamo; John R F Gladman Journal: BMC Geriatr Date: 2012-06-25 Impact factor: 3.921